Monte Rosa Therapeutics (GLUE) Operating Expenses: 2023-2025
Historic Operating Expenses for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $45.7 million.
- Monte Rosa Therapeutics' Operating Expenses rose 27.98% to $45.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $173.0 million, marking a year-over-year increase of 20.20%. This contributed to the annual value of $156.7 million for FY2024, which is 9.37% up from last year.
- Monte Rosa Therapeutics' Operating Expenses amounted to $45.7 million in Q3 2025, which was up 18.05% from $38.7 million recorded in Q2 2025.
- Monte Rosa Therapeutics' Operating Expenses' 5-year high stood at $47.6 million during Q4 2024, with a 5-year trough of $34.3 million in Q1 2023.
- In the last 3 years, Monte Rosa Therapeutics' Operating Expenses had a median value of $37.2 million in 2023 and averaged $38.7 million.
- Over the last 5 years, Monte Rosa Therapeutics' Operating Expenses had its largest YoY gain of 36.66% in 2024, and its largest YoY loss of 3.31% in 2024.
- Over the past 3 years, Monte Rosa Therapeutics' Operating Expenses (Quarterly) stood at $34.9 million in 2023, then skyrocketed by 36.66% to $47.6 million in 2024, then climbed by 27.98% to $45.7 million in 2025.
- Its Operating Expenses stands at $45.7 million for Q3 2025, versus $38.7 million for Q2 2025 and $40.9 million for Q1 2025.